Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Change in Accured Expenses (2024 - 2026)

Prelude Therapeutics' Change in Accured Expenses history spans 3 years, with the latest figure at -$6.6 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 66.38% to -$6.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$5.6 million, a 712.88% decrease, with the full-year FY2025 number at -$3.0 million, down 268.81% from a year prior.
  • Change in Accured Expenses hit -$6.6 million in Q1 2026 for Prelude Therapeutics, down from -$515000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for PRLD hit a ceiling of $2.1 million in Q3 2024 and a floor of -$6.6 million in Q1 2026.
  • Historically, Change in Accured Expenses has averaged -$1.2 million across 3 years, with a median of -$367000.0 in 2025.
  • The widest YoY moves for Change in Accured Expenses: up 52.53% in 2025, down 132.87% in 2025.
  • Tracing PRLD's Change in Accured Expenses over 3 years: stood at $1.6 million in 2024, then plummeted by 132.87% to -$515000.0 in 2025, then crashed by 1181.94% to -$6.6 million in 2026.
  • Business Quant data shows Change in Accured Expenses for PRLD at -$6.6 million in Q1 2026, -$515000.0 in Q4 2025, and -$367000.0 in Q3 2025.